| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2022 ( Subtotal = $0 ) |
| | 2022 | 2020 | CERFLUX INC | 215 RICHARD ARRINGTON JR BLVD N | BIRMINGHAM | AL | 35203-3770 | JEFFERSON | USA | R43CA254493 | Development of personalized ex vivo predictive technology for rapidly matching patient tumors with chemotherapy regimens before treatment. | 000 | 1 | NIH | 12/17/2021 | $0 |
|
| Issue Date FY: 2021 ( Subtotal = $52,000 ) |
| | 2021 | 2021 | CERFLUX, INC. | 2140 11TH AVE S STE 308 | BIRMINGHAM | AL | 35205-2841 | JEFFERSON | USA | R43CA254493 | Development of personalized ex vivo predictive technology for rapidly matching patient tumors with chemotherapy regimens before treatment. | 000 | 1 | NIH | 5/24/2021 | $52,000 |
|
| Issue Date FY: 2020 ( Subtotal = $249,148 ) |
| | 2020 | 2020 | CERFLUX, INC. | 2140 11TH AVE S STE 308 | BIRMINGHAM | AL | 35205-2841 | JEFFERSON | USA | R43CA254493 | Development of personalized ex vivo predictive technology for rapidly matching patient tumors with chemotherapy regimens before treatment. | 000 | 1 | NIH | 9/10/2020 | $249,148 |
|
|
